Skip to main content

Table 3 Brain PFS Heterogeneity by Treatment Effects using Log-rank test

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Best brain response CR PR Any Response SD ≥ 6mo SD < 6mo PD Total Log-rank test for treatment,P-value
Treatment before entering the study No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI) No. Median brain PFS, wk (95 % CI)  
No 0 NE 2 59.3 (NE) 0 NE 1 30.4 (NE) 1 12.6 (NE) 2 9.2 (6.4-12.0) 6 21.5 (12.0-59.3) 0.6281
Excision/GKS/ SRS/FSRT 4 32.4 (21.6-34.7) 0 NE 6 27.5 (20.0-53.7) 2 36.4 (28.1-44.7) 0 NE 0 NE 12 31.4 (22.1-34.7)  
WBRT 2 84.3 (NE) 4 21.1 (15.9-NE) 13 40.9 (25.0-59.0) 5 35.0 (26.1-NE) 3 17.9 (12.6-24.0) 5 10.7 (4.0-32.6) 32 31.1 (23.7-41.0)  
Subtotal 6 33.6 (30.4-84.3) 6 42.4 (16.6-NE) 19 32.9 (23.7-54.1) 8 33.2 (28.1-48.6) 4 15.2 (12.6-24.0) 7 10.7 (6.4-12.1) 50 30.6 (24.0-34.7)  
IT MTX      1 17.0 (NE)        1 17.0 (NE)  
Total 6 33.6 (30.4-84.3) 6 42.4 (16.6-NE) 20 32.8 (22.1-54.1) 8 33.2 (28.1-48.6) 4 15.2 (12.6-24.0) 7 10.7 (6.4-12.1) 51 30.4 (23.7-34.7)  
  1. CR, complete response; FSRT, fractionated stereotactic radiotherapy; GKS, gamma knife surgery; IT MTX, intrathecal methotrexate; PR, partial response; PD, progressive disease; SD, stable disease; SRS, stereotactic radio-surgery; WBRT, whole-brain radiotherapy; NE, not estimable.